(Q43029247)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20540898%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

review article

1 reference

title

Importance of HDL cholesterol in atherothrombosis: how did we get here? Where are we going? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20540898%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author

Carlos G Santos-Gallego

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20540898%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Juan José Badimón

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20540898%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Lina Badimón

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20540898%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

language of work or name

Spanish

0 references

publication date

1 June 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20540898%20AND%20SRC:MED&resulttype=core&format=json

Revista Española de Cardiología

5 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20540898%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

63 Suppl 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20540898%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

20-35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20540898%20AND%20SRC:MED&resulttype=core&format=json

Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization

5 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

[Epidemiology of ischaemic heart disease in Spain: estimation of the number of cases and trends from 1997 to 2005]

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Ezetimibe: one step beyond in the battle against atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Plaque progression and regression in atherothrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

High-density lipoprotein cholesterol and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. The Lipid Research Clinics Program Epidemiology Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Prevalence of risk factors in men with premature coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Endothelial and antithrombotic actions of HDL.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Effects of colestipol-niacin therapy on human femoral atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP).

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Extended-release niacin or ezetimibe and carotid intima-media thickness.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Bezafibrate in men with lower extremity arterial disease: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Effects of torcetrapib in patients at high risk for coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Effect of torcetrapib on the progression of coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

High-density lipoprotein as a therapeutic target: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Effects of the amount and intensity of exercise on plasma lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50 to 65 years

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Effect of Aerobic Exercise Training on Serum Levels of High-Density Lipoprotein Cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Cigarette smoking and HDL cholesterol the Framingham offspring study

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Alcohol intake and the risk of coronary heart disease mortality in persons with older-onset diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

The inverse relation between fish consumption and 20-year mortality from coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

HDL-cholesterol: is it really good? Differences between apoA-I and HDL.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

1 reference

7 January 2021

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Safety and tolerability of dalcetrapib

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Liver X receptors as integrators of metabolic and inflammatory signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Identification of macrophage liver X receptors as inhibitors of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Update on strategies to increase HDL quantity and function

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Oral Synthetic Phospholipid (DMPC) Raises High-Density Lipoprotein Cholesterol Levels, Improves High-Density Lipoprotein Function, and Markedly Reduces Atherosclerosis in Apolipoprotein E–Null Mice

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021

Phosphatidylinositol increases HDL-C levels in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2810%2970150-0

7 January 2021